sur Newron Pharmaceuticals S.p.A. (isin : IT0004147952)
Newron Pharmaceuticals Unveils H1 2025 Results and Strategic Advancements
Milan-based Newron Pharmaceuticals S.p.A. released its H1 2025 financial results and reported significant progress in its clinical programs. Notably, Newron secured regulatory approval for the ENIGMA-TRS Phase III trial, targeting treatment-resistant schizophrenia, with patient enrollment commencing in August 2025.
The company also expanded its strategic partnerships, signing a licensing agreement with Myung In Pharm for South Korea and strengthening ties with EA Pharma in Japan. This aligns with their strategy to enhance global reach and explore additional partnerships for evenamide's commercialization.
Financially, Newron recorded a noticeable improvement, with an increase in income and a reduction in net loss, coupled with a strong cash position, signaling robust health to support ongoing initiatives.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Newron Pharmaceuticals S.p.A.